MENU
APR 02, 2020 10:00 AM PDT

SARS-CoV-2 (CoVID-19: Emergence, Biology, and Countermeasures)

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Director, Division of Infectious Diseases, Craig-Weaver Professor of Pediatrics, Professor of Pathology, Microbiology & Immunology, Professor at Vanderbilt University
    Biography
      Mark Denison M.D. is the Craig-Weaver Professor of Pediatrics, Pathology, Microbiology & Immunology at Vanderbilt University Medical Center in Nashville, TN. Dr. Denison has performed over 25 years of NIH-funded research focused on the replication, pathogenesis, and evolution of coronaviruses, a family of RNA viruses from which SARS-CoV emerged. Coronaviruses cause respiratory infections in humans and increasingly are thought to be ubiquitous among mammalian species. Notably, a large number of novel coronaviruses have been identified in bats, suggesting that bats may be critical for the emergence of coronaviruses in other species. Coronaviruses may have unique potential for cross-species movement. They encode novel RNA synthesis and probable RNA proofreading functions, thereby conferring the ability to maintain large and complex genomes and to respond to host or other environmental changes. The Denison lab focuses on determining the mechanisms of coronavirus evolution and host species movement and adaptation, using synthetic biology and reverse genetics. Dr. Denison has served on the steering committee for the Southeast Regional Center of Excellence in Emerging Infections and Biodefense for the past eight years. In addition, he is the Chair of the Vanderbilt Institutional Biosafety Committee and has served on multiple Government and international panels involved in review or consideration of biodefense, biosecurity, and synthetic biology.

    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    JUL 22, 2020 10:00 AM PDT
    C.E. CREDITS
    JUL 22, 2020 10:00 AM PDT
    DATE: July 23, 2020 TIME: 10:00 am PDT The SARS-CoV-2 pandemic has taken a toll on many sectors of the medical community. As the pandemic took a grip on the laboratory, the need for diagnost...
    MAY 12, 2020 9:00 AM PDT
    C.E. CREDITS
    MAY 12, 2020 9:00 AM PDT
    NEW DATE: Date: May 12, 2020 Time: 9:00am PDT, 12:00pm EDT...
    JUN 30, 2020 9:00 AM PDT
    C.E. CREDITS
    JUN 30, 2020 9:00 AM PDT
    DATE: June 30, 2020 TIME: 9:00am PDT, 12:00pm EDT QC laboratories perform a critical role in demonstrating pharmaceutical products are consistently manufactured, safe, potent, and pure. At t...
    Loading Comments...
    Show Resources